Literature DB >> 22847744

Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones.

David J Konieczkowski1, Levi A Garraway.   

Abstract

Two recent papers identify KRAS activation as a mechanism of acquired resistance to EGFR blockade in colorectal cancer. In doing so, they suggest that resistance to single-agent EGFR blockade will be unavoidable because these alterations exist as latent subclones within the tumor even prior to the initiation of therapy.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22847744      PMCID： PMC3541651          DOI： 10.1038/cr.2012.115

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


  6 in total

1.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Authors:  Sandra Misale; Rona Yaeger; Sebastijan Hobor; Elisa Scala; Manickam Janakiraman; David Liska; Emanuele Valtorta; Roberta Schiavo; Michela Buscarino; Giulia Siravegna; Katia Bencardino; Andrea Cercek; Chin-Tung Chen; Silvio Veronese; Carlo Zanon; Andrea Sartore-Bianchi; Marcello Gambacorta; Margherita Gallicchio; Efsevia Vakiani; Valentina Boscaro; Enzo Medico; Martin Weiser; Salvatore Siena; Federica Di Nicolantonio; David Solit; Alberto Bardelli
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

2.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Marc Peeters; Salvatore Siena; Yves Humblet; Alain Hendlisz; Bart Neyns; Jean-Luc Canon; Jean-Luc Van Laethem; Joan Maurel; Gary Richardson; Michael Wolf; Rafael G Amado
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

3.  Cetuximab for the treatment of colorectal cancer.

Authors:  Derek J Jonker; Chris J O'Callaghan; Christos S Karapetis; John R Zalcberg; Dongsheng Tu; Heather-Jane Au; Scott R Berry; Marianne Krahn; Timothy Price; R John Simes; Niall C Tebbutt; Guy van Hazel; Rafal Wierzbicki; Christiane Langer; Malcolm J Moore
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

4.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

5.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

6.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Authors:  Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962
  6 in total
  2 in total

Review 1.  Precision medicine for advanced prostate cancer.

Authors:  Stephanie A Mullane; Eliezer M Van Allen
Journal:  Curr Opin Urol       Date:  2016-05       Impact factor: 2.309

Review 2.  The Risks of miRNA Therapeutics: In a Drug Target Perspective.

Authors:  Song Zhang; Zhujun Cheng; Yanan Wang; Tianyu Han
Journal:  Drug Des Devel Ther       Date:  2021-02-22       Impact factor: 4.162
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.